By Peter Damiri Vice President of Programs and Services As you may have recently seen, MSAA focused much-needed attention, education and resources on the topic of MS and the Family […]
Read News ArticleSearch Results for:
Research News: FDA Approves Two New Oral Treatments for Relapsing Forms of MS, Including Active SPMS
Mayzent® (Siponimod) Tablets In a release dated March 26, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mayzent® (siponimod) oral tablets to treat adults with […]
Read News ArticleAsk the Doctor: Treatment Questions and Diagnostic Issues
Dr. Jack Burks By Dr. Jack Burks MSAA’s Chief Medical Consultant Q: I am a 53-year-old female just recently diagnosed with CIS (clinically isolated syndrome), although I have experienced MS […]
Read News ArticleUp Front: A Five-Year Strategic Plan for Progress
Gina Ross Murdoch By Gina Ross Murdoch MSAA President and CEO Now that spring has arrived, this is a time to look ahead and experience exciting new beginnings. The same […]
Read News ArticleThe Motivator – Winter/Spring 2019
View/Download PDF View Digital Edition Cover Story Planning for Your Future By Susan Wells Courtney This article defines the legal and financial decisions and documents that need to be considered […]
Read News ArticleMavenclad® (Cladribine) Tablets Approved by the FDA for Adults with Relapsing Forms of MS, Including Active SPMS
In a news release dated March 29, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mavenclad® (cladribine) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval is for individuals with relapsing-remitting MS (RRMS) and for individuals with active secondary-progressive MS (SPMS).
Read News ArticleMayzent® (Siponimod) Tablets Approved by the FDA for Adults with Relapsing Forms of MS, Including Active SPMS
In a news release dated March 26, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mayzent® (siponimod) oral tablets to treat adults with relapsing forms […]
Read News ArticleWhat Happened to My Copay Assistance? – Download PDF
Download the PDF of the MSAA’s Publication – What Happened to My Copay Assistance?: This brochure explains copay accumulators and the potential impact they may have on the cost of one’s healthcare.
Read News ArticleWhat Happened to My Copay Assistance?
MSAA’s publication What Happened to My Copay Assistance? explains copay accumulators and the potential impact they may have on the cost of one’s healthcare.
Read News ArticleWhat’s New in MS Research – March 2019
The opening months of 2019 saw significant research advances on many fronts in multiple sclerosis (MS). A sophisticated analysis of data using healthcare claims found that the number of people in the United States living with MS is more than twice as high as previously estimated. Dietary studies sounded a cautionary note for people with MS drinking soda and many other sweetened beverages, and a hopeful note on the potential for flavonoid-rich cocoa to reduce MS-associated fatigue. A promising stem-cell therapy is moving forward in the clinical-trials process, while the FDA is considering whether to approve a new disease-modifying therapy (DMT).
Read News Article